AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02384070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
Study NCT00622219 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized Drug Testing Trial
Description: Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
Study NCT02078869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vaginal progesterone suppositories
Description: Vaginal Promterium 200 mg , 3 times a day
Study NCT00239083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Study NCT00724217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Process 21 Day Purification Program (SPPP)
Description: The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
Study NCT00724217 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Process 21 Day Purification Program (SPPP)
Description: The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
Study NCT00606502 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: 1-1.25 mg orally~Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment.
Study NCT03354455 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation
Description: Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot.
Study NCT03354455 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive transcranial magnetic stimulation
Description: Frequency: 1 Hz., Pulse shape: biphasic, Duration: 30 minutes (1800 pulses).~Neuronavigation: MRI-guided and robot-assisted neuronavigation using Localite software and an Axilum robot.
Study NCT01812135 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 400 U EV71 vaccine with adjuvant
Description: 400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
Study NCT01997021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: US
Description: US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
Study NCT01997021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IW
Description: IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
Study NCT01997021 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CW
Description: CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
Study NCT02394691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
Study NCT02394691 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: transcranial direct current stimulation
Description: anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
Study NCT00252174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 1 Active Methylenedioxymethamphetamine
Description: Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg.
Study NCT00252174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stage 1 Low dose Methylenedioxymethamphetamine
Description: Drug:~Dosage form: capsule~Dosage frequency and duration for the control arm (4 subjects):~Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg.
Study NCT00252174 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychotherapy conducted with low or active dose MDMA
Study NCT00252174 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy
Description: Psychotherapy conducted with low or active dose MDMA
Study NCT00252174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stage 2 Active Methylenedioxymethamphetamine
Description: Administered open label Dosage form: capsule~Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):~Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg.
Study NCT04134754 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 6% Carbon dioxide/50% oxygen/balance nitrogen mixture
Description: In the hypercapnic ventilatory response (HCVR) test, the subject will rebreathe a gas mixture that has 6% carbon dioxide and 50% oxygen. This test has been performed for decades for research and clinical purposes. The effects of carbon dioxide inhalation are short lived and do not cause long term consequences. the hypercapnic ventilatory response (HCVR), we will have you
Study NCT04507594 — intervention group
Intervention type: PROCEDURE
Intervention: Lung lobectomy OR esophagus cancer resection
Description: Lunge lobectomy (total) Resection of esophagus cancer
Study NCT00603863 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMMU-107 (hPAM4)
Description: 90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
Study NCT01331759 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuropattern™
Description: Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
Study NCT01331759 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Neuropattern™
Description: Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
Study NCT03949023 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of Care Cerebral Angiogram Group
Description: Subjects will undergo the standard of care cerebral angiogram and any intervention(s) (when applicable) that were discussed with their provider, following the standard procedural protocol for the procedure at WFBMC. There are no additional interventions or changes to the planned intervention(s) that will take place by agreeing to participate in the study.~The data collected from this procedure, following the standard of care protocol, will include the following: force of injection of contrast material for each angiographic run (peak pressure associated with injection, duration of peak, and area under pressure curve), volume of contrast utilized, images from the procedure, measurements of vessel diameter at defined distances from the catheter tip utilizing the images, catheter type, any additional device(s) (when applicable) utilized during the procedure, and if spasmolytic agents are utilized (including dose and time of administration).
Study NCT03253081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PARENT focused intervention
Description: The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
Study NCT03253081 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CHILD focused intervention
Description: The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
Study NCT03170440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation location 1
Description: Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
Study NCT03170440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation location 1
Description: Non-invasive stimulation by transcutaneous electrical nerve stimulation device in test location
Study NCT03170440 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation location 2
Description: Stimulation will be performed using electrodes placed in alternate location.
Study NCT03170440 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous nerve stimulation location 2
Description: Stimulation will be performed using electrodes placed in alternate location.
Study NCT03827317 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: [18F]GE-226
Description: \[18F\]GE-226 is a radiolabelled Affibody® tracer which binds to the HER2 receptor with high affinity at a different epitope than trastuzumab. The active molecule is a 61 amino acid peptide that is modified site-specifically with one fluorobenzaldehyde molecule at the C-terminal.
Study NCT03898011 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lamotrigine
Description: Lamotrigine, 100 mg Tablets, manufactured by Pharmtechnology LLC, Belarus
Study NCT00177216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
Study NCT03898011 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lamictal
Description: Lamictal®, 100 mg Tablets, marketed by GlaxoSmithKline Trading CJSC, Russia
Study NCT00177216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
Study NCT00177216 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
Study NCT03123198 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy
Description: DBT is a multimodal comprehensive psychosocial treatment.
Study NCT03418805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Advil Ibuprofen table 200 mg
Description: Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration.
Study NCT03418805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Motrin IB Ibuprofen Tablets 200 mg
Description: Administration of the comparator drug:~Three tablets (dosing at a 4-hour interval, q4h) of reference ibuprofen standard products, followed by 24 hours after the first dose administration.
Study NCT03418805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen CR Tablets 600 mg
Description: Administration of the investigational product:~Single oral dose of IBUCR, followed by 28 and 32 hours after the dose administration for fasted and fed studies, respectively
Study NCT01599897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ID93 + GLA-SE
Description: ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
Study NCT03158025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant tablets, over-encapsulated
Description: Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
Study NCT01599897 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ID93 alone
Description: ID93 antigen alone. 3 injections and Days 0, 28, and 56.
Study NCT01527253 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Synergistic food basket
Description: A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
Study NCT03178292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin 500Mg daily for 5 days
Study NCT03178292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Oral Tablet daily for 5 days
Study NCT03933605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam and palonosetron group
Description: intravenous midazolam and palonosetron administraion as prevention of postoperative nausea and vomiting
Study NCT03933605 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palonosetron group
Description: intravenous palonosetron administraion as prevention of postoperative nausea and vomiting
Study NCT04461197 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: customised foot orthoses
Description: The foot orthoses for group A were custom made using phenolic foam molds of the feet. Separated molds were made of both feet for all the participants. . The insole was made based on a positive mold of plaster with 45 Shore cork materials with horizontal thrusts just proximal to the metatarsal heads, with the intention of correcting the pathological subtalar pronation, with a 3mm bilateral raising of the heel and a bilateral latex metatarsal bar.
Study NCT04461197 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: orthotic insole
Description: For group B, a flat insole of polyester resin was made, fitting it to the foot's size.
Study NCT02872753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACP
Description: Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
Study NCT02872753 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Meniscectomy
Description: Patients will receive standard arthroscopic meniscectomy
Study NCT01372761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-433
Description: Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study NCT01372761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
Study NCT03024606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: text messages focused on smoking cessation and pregnancy
Description: The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
Study NCT03189329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine hydrochloride
Description: Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
Study NCT03189329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% levobupivacaine
Description: and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
Study NCT01667302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiotherapy followed by chemotherapy
Description: Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
Study NCT01161498 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Administered by intratumoral injection
Study NCT01161498 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: 70 grays of radiation administered in 35 fractions over 7 weeks
Study NCT01161498 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 70 grays of radiation administered in 35 fractions over 7 weeks
Study NCT01161498 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered by intravenous infusion
Study NCT01161498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered by intravenous infusion
Study NCT00064714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 (exenatide)
Description: Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
Study NCT00064714 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclizumab (immunosuppressive)
Description: 2 mg/kg intravenously infused over 30 minutes every month for 12 months
Study NCT04426461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: Behavioral activation will be delivered as a 10-week, manualized, behavioral intervention focused on enhancing engagement in meaningful and reinforcing activities.
Study NCT04426461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure-based therapy
Description: Exposure-based therapy will be delivered as a 10-week, manualized, behavioral intervention focused on decreasing avoidance to allow for inhibitory learning and challenging negative expectations.
Study NCT04426461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy
Description: Supportive therapy will be delivered as a 10-week, manualized intervention focused on encouraging patients to talk openly about their thoughts, emotions, and any past or current concerns.
Study NCT03996863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Otoband
Description: Participants during infusion following chemotherapy will wear the Otoband set at normal power (effective) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.